Frequency Specific Microcurrent Therapy for Mild Traumatic Brain Injury

Dizziness Clinical Trial

Official title:

Frequency Specific Microcurrent Therapy for Mild Traumatic Brain injury-a Single Center Double-blind Randomized Sham-controlled Trail

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06245967
• Other study ID #: CMUH112-REC3-176
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 15, 2024
• Est. completion date: February 28, 2026

Study information

• Verified date: January 2024
• Source: China Medical University Hospital
• Contact: I HAN Hsiao
• Phone: +886933668642
• Email: coolfishing2002[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with mild traumatic brain injury (mTBI) may experience spontaneous recovery within 7-10 days, but some continue to exhibit symptoms such as headache, dizziness, vertigo, poor concentration, and cognitive dysfunction. Effective treatments for these symptoms are currently lacking. Frequency Specific Microcurrent(FSM) has received approval from the U.S. FDA for use in neuroinflammatory conditions. Our study aims to evaluate the efficacy of FSM by using FSM device ,IS02LCDs Stimulator (Ru Yi Health ltd. Co,Taiwan R.O.C), on symptom improvement in 52 patients with mild TBI

Description:

This study is a single center double-blind randomized sham-controlled trail.We aims to recruit 52 mild traumatic brain injury participants with symptoms for more than 10 days.Clinical assessments include Post-Concussion Symptom Scale (PCSS) scores, and the amount of medication used for symptom management. These 52 participants will be 1:1 randomly allocated into two groups (1) sham FSM with symptom management medication and (2) True FSM with symptom management medication. The treatment period will last two weeks, with a total of six therapy sessions. Following treatment, a four-week observation period will be conducted. The primary outcome measurement will be changes in the Post-Concussion Symptom Scale (PCSS) scores, recorded at baseline, after the third treatment session, at the end of treatment, and at the end of the observation period. Secondary outcome measures will include the amount of medication used for symptom management. The safety evaluated index is the adverse event rate for two groups. These assessments aim to evaluate the therapeutic benefits of FSM for mild traumatic brain injury.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 52
• Est. completion date: February 28, 2026
• Est. primary completion date: February 28, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age between 20 and 65, inclusive, for both males and females.

2. History of traumatic brain injury with a loss of consciousness lasting less than 30 minutes, initial Glasgow Coma Scale (GCS) score ranging from 13 to 15.

3. Presence of persistent post-concussion symptoms starting from the day of injury and lasting for more than ten days.

4. Complete consciousness or decision-making capacity at the time of enrollment.

5. Brain imaging through CT or MRI indicating the absence of significant midline shift, no evident damage to the brainstem (excluding the pyramidal tract), or thalamus. Each brain lobe lesion should not exceed 30% of the respective cerebral hemisphere.

Exclusion Criteria:

1. Individuals below 20 years or above 65 years of age, regardless of gender.

2. History of traumatic brain injury with a loss of consciousness exceeding 30 minutes, initial Glasgow Coma Scale (GCS) score less than 13.

3. Not a first-time occurrence of traumatic brain injury.

4. Brain imaging through CT or MRI revealing significant midline shift, evident damage to the brainstem or thalamus, with each brain lobe lesion exceeding 30% of the respective cerebral hemisphere.

5. Presence of comorbidities such as cancer, depression.

Related Conditions & MeSH terms

• Brain Concussion
• Brain Injuries
• Brain Injuries, Traumatic
• Craniocerebral Trauma
• Dizziness
• Headache
• Headaches Posttraumatic
• Post-Traumatic Headache
• Trauma, Head

Intervention

Device:
• Frequency specific microcurrent therapy
Concussion protocol
• Sham Frequency specific microcurrent therapy
Shan concussion protocol

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
China Medical University Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Post-Concussion Symptom Scale (PCSS) scores	The Post-Concussion Symptom Scale (PCSS) is used to assess the number and intensity of symptoms after a concussion/mild traumatic brain injury.	1.5 month
Secondary	the amount of medication used for symptom management	the amount of medication used for symptom management	1.5 month